- Home
- LDWY vs NLSP Comparison
LDWY vs NLSP Comparison
Compare LDWY & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- NLSP
- Stock Information
- Founded
- LDWY 1990
- NLSP 2015
- Country
- LDWY United States
- NLSP Switzerland
- Employees
- LDWY N/A
- NLSP N/A
- Industry
- LDWY Advertising
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- NLSP Health Care
- Exchange
- LDWY Nasdaq
- NLSP Nasdaq
- Market Cap
- LDWY 6.7M
- NLSP 243.8M
- IPO Year
- LDWY 1991
- NLSP 2021
- Fundamental
- Price
- LDWY $3.42
- NLSP $4.96
- Analyst Decision
- LDWY
- NLSP
- Analyst Count
- LDWY 0
- NLSP 0
- Target Price
- LDWY N/A
- NLSP N/A
- AVG Volume (30 Days)
- LDWY 9.9K
- NLSP 34.6K
- Earning Date
- LDWY 11-11-2024
- NLSP 11-01-2024
- Dividend Yield
- LDWY N/A
- NLSP N/A
- EPS Growth
- LDWY N/A
- NLSP N/A
- EPS
- LDWY N/A
- NLSP N/A
- Revenue
- LDWY $24,813,000.00
- NLSP N/A
- Revenue This Year
- LDWY N/A
- NLSP N/A
- Revenue Next Year
- LDWY N/A
- NLSP N/A
- P/E Ratio
- LDWY N/A
- NLSP N/A
- Revenue Growth
- LDWY N/A
- NLSP N/A
- 52 Week Low
- LDWY $3.02
- NLSP $4.08
- 52 Week High
- LDWY $6.88
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- LDWY 46.04
- NLSP 46.37
- Support Level
- LDWY $3.34
- NLSP $4.52
- Resistance Level
- LDWY $3.66
- NLSP $5.64
- Average True Range (ATR)
- LDWY 0.20
- NLSP 0.48
- MACD
- LDWY 0.04
- NLSP 0.07
- Stochastic Oscillator
- LDWY 62.50
- NLSP 55.44
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.